First hormone replacement therapy for parathyroid disorder
The European Medicines Agency has recommended granting a conditional marketing authorisation in the EU for an orphan medicine proposed as a treatment for chronic hypoparathyroidism, in patients poorly controlled using standard treatments.European Medicines Agency
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
More News: Endocrinology | European Medicines Agency (EMA) | Hormone Replacement Therapy | Hormones | Marketing